FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969451858> ?p ?o ?g. }

• W2969451858 endingPage "1318" @default.
• W2969451858 startingPage "1318" @default.
• W2969451858 abstract "Abstract Treatment of acute myeloid leukemia remains inadequate, largely due to our limited understanding of therapy resistance and lack of effective therapeutic targets. Recently, we and others have used functional genomic and proteomic methods to elucidate the mechanisms of therapy resistance. These studies have revealed the existence of privileged populations of AML cells with distinct signaling properties. AML is known to have leukemia stem cells (LSCs), which exhibit self-renewal and cell-cycle quiescence, and contribute to chemotherapy resistance. However, their prospective isolation has been hindered by their variable immunophenotypes, constituting an important gap to understanding their biology, as a prelude to developing improved therapies. Here, we used chemical protein labeling to prospectively isolate AML quiescent and stem cells from primary patient leukemias, based on proteome production and renewal. First, we developed optimized protein-labeling conditions to preserve stem cell function, as demonstrated by transplantation of labeled mouse hematopoietic stem cells into lethally irradiated recipients. We applied this method to prospectively isolate primary patient AML quiescent cells upon transplanting labeled specimens into immunodeficient NSG mice. These studies showed that label-retaining, but not their label non-retaining populations, are comprised by AML stem cells, as evidenced by serial transplantation and limiting dilution (Figure 1). Using genome sequencing of label-retaining and non-retaining populations, we confirmed the absence of genetic mutations associated with AML proteome quiescence, consistent with their epigenetic basis. To confirm this epigenetic mechanism directly, we performed re-labeling experiments, observing reversible development of quiescent stem cells from their proliferating counterparts. To define the epigenetic mechanisms of AML quiescence, we used assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) and mRNA sequencing (RNA-seq) of label-retaining versus non-retaining populations from three different therapy-resistant MLL-, MOZ-, and NUP98-rearranged patient leukemias. Gene set enrichment analysis demonstrated significant association with reported gene expression programs associated with hematopoietic and AML stem cell function, and FACS analysis showed the presence of some but not all reported stem cell surface markers, including CD34, CD38, CD117, CD90, CD45RA, and CD123. Remarkably, in spite of the biological differences among these subtypes, we observed a common set of genes and differentially accessible chromatin loci in AML quiescent as compared to proliferating cells. Motif analysis revealed that differentially accessible chromatin in the label-retaining cell population was predominantly comprised by the E26 transformation-specific (ETS) family transcription factor (TF)-binding motifs. For example, the ETS-related gene (ERG)-binding motif covered more than 50% of differentially accessible chromatin in the label-retaining cell population (p = 10e-7). Consistently, label-retaining quiescent cells exhibited significant induction of gene expression programs associated with ETS transcription factor function. In summary, this work presents a functional approach for the prospective isolation of primary patient AML quiescent cells. Human AML quiescent cells constitute a distinct population with leukemia-initiating and self-renewal capacity, as well as epigenetic plasticity and reversible induction in diverse genetic disease subtypes. We anticipate that the reported gene expression and chromatin profiles, including those controlled by ETS transcription factors, should define their control mechanisms and targets for improved therapy. Disclosures No relevant conflicts of interest to declare." @default.
• W2969451858 created "2019-08-29" @default.
• W2969451858 creator A5041999611 @default.
• W2969451858 creator A5055053315 @default.
• W2969451858 creator A5065570052 @default.
• W2969451858 creator A5069334303 @default.
• W2969451858 creator A5079952504 @default.
• W2969451858 date "2018-11-29" @default.
• W2969451858 modified "2023-09-30" @default.
• W2969451858 title "Functional Profiling of Patient AML Stem Cells Reveals Mechanisms of Epigenetic Plasticity Controlling Therapy Resistance" @default.
• W2969451858 doi "https://doi.org/10.1182/blood-2018-99-114433" @default.
• W2969451858 hasPublicationYear "2018" @default.
• W2969451858 type Work @default.
• W2969451858 sameAs 2969451858 @default.
• W2969451858 citedByCount "0" @default.
• W2969451858 crossrefType "journal-article" @default.
• W2969451858 hasAuthorship W2969451858A5041999611 @default.
• W2969451858 hasAuthorship W2969451858A5055053315 @default.
• W2969451858 hasAuthorship W2969451858A5065570052 @default.
• W2969451858 hasAuthorship W2969451858A5069334303 @default.
• W2969451858 hasAuthorship W2969451858A5079952504 @default.
• W2969451858 hasBestOaLocation W29694518581 @default.
• W2969451858 hasConcept C104317684 @default.
• W2969451858 hasConcept C109159458 @default.
• W2969451858 hasConcept C126322002 @default.
• W2969451858 hasConcept C150194340 @default.
• W2969451858 hasConcept C190727270 @default.
• W2969451858 hasConcept C203014093 @default.
• W2969451858 hasConcept C2778461978 @default.
• W2969451858 hasConcept C2778729363 @default.
• W2969451858 hasConcept C2780737395 @default.
• W2969451858 hasConcept C28328180 @default.
• W2969451858 hasConcept C2911091166 @default.
• W2969451858 hasConcept C41091548 @default.
• W2969451858 hasConcept C502942594 @default.
• W2969451858 hasConcept C54355233 @default.
• W2969451858 hasConcept C71924100 @default.
• W2969451858 hasConcept C86803240 @default.
• W2969451858 hasConcept C95444343 @default.
• W2969451858 hasConceptScore W2969451858C104317684 @default.
• W2969451858 hasConceptScore W2969451858C109159458 @default.
• W2969451858 hasConceptScore W2969451858C126322002 @default.
• W2969451858 hasConceptScore W2969451858C150194340 @default.
• W2969451858 hasConceptScore W2969451858C190727270 @default.
• W2969451858 hasConceptScore W2969451858C203014093 @default.
• W2969451858 hasConceptScore W2969451858C2778461978 @default.
• W2969451858 hasConceptScore W2969451858C2778729363 @default.
• W2969451858 hasConceptScore W2969451858C2780737395 @default.
• W2969451858 hasConceptScore W2969451858C28328180 @default.
• W2969451858 hasConceptScore W2969451858C2911091166 @default.
• W2969451858 hasConceptScore W2969451858C41091548 @default.
• W2969451858 hasConceptScore W2969451858C502942594 @default.
• W2969451858 hasConceptScore W2969451858C54355233 @default.
• W2969451858 hasConceptScore W2969451858C71924100 @default.
• W2969451858 hasConceptScore W2969451858C86803240 @default.
• W2969451858 hasConceptScore W2969451858C95444343 @default.
• W2969451858 hasIssue "Supplement 1" @default.
• W2969451858 hasLocation W29694518581 @default.
• W2969451858 hasOpenAccess W2969451858 @default.
• W2969451858 hasPrimaryLocation W29694518581 @default.
• W2969451858 hasRelatedWork W2013250198 @default.
• W2969451858 hasRelatedWork W2044401234 @default.
• W2969451858 hasRelatedWork W2046259286 @default.
• W2969451858 hasRelatedWork W2079497260 @default.
• W2969451858 hasRelatedWork W2119511363 @default.
• W2969451858 hasRelatedWork W2963322175 @default.
• W2969451858 hasRelatedWork W2997253459 @default.
• W2969451858 hasRelatedWork W4210379329 @default.
• W2969451858 hasRelatedWork W4310701073 @default.
• W2969451858 hasRelatedWork W4313260741 @default.
• W2969451858 hasVolume "132" @default.
• W2969451858 isParatext "false" @default.
• W2969451858 isRetracted "false" @default.
• W2969451858 magId "2969451858" @default.
• W2969451858 workType "article" @default.